RNA-seq expression data from the TCGA demonstrated that TKT was significantly overexpressed in several cancers, including bladder cancer (BLCA), cervical cancer, colon cancer, esophageal cancer, kidney chromophobe (KICH), kidney papillary cell carcinoma, LIHC, lung adenocarcinoma, prostate cancer (PRAD), rectal cancer, thyroid cancer (THCA) and uterine corpus endometrial cancer (UCEC), but exhibited low expression levels in breast cancer (Figure 2A). This evidence concerns the gene TKT and prostate cancer.